Cover Image

Second-generation antipsychotic and diabetes mellitus in children and adolescents

Second generation antipsychotics (SGA) are used in children for the treatment of various psychiatric diseases, including pervasive developmental disorders. These drugs can cause metabolic effects as hyperglycemia and diabetes. A 16-year-old young-boy, diagnosed with autism, developed diabetes mellit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carlo Ripoli (Author), Anna Paola Pinna (Author), Faustina Podda (Author), Roberta Zanni (Author), Maria Giada Tronci (Author), Anna Maria Nurchi (Author)
Format:	Book
Published:	PAGEPress Publications, 2017-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
by: Giuseppe Caruso, et al.
Published: (2020)

Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management
by: Krill RA, et al.
Published: (2014)

A distal renal tubular acidosis showing hyperammonemia and hyperlactacidemia
by: C. Ripoli, et al.
Published: (2012)

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
by: Sebastiano Alfio Torrisi, et al.
Published: (2020)

The impact of atypical antipsychotics on the development of type 2 diabetes mellitus
by: Sabina E. Kurtmambetova, et al.
Published: (2024)

A narrative review of metabolic monitoring of adult prescribed second-generation antipsychotics for severe mental illness
by: Pooja Gopal Poojari, et al.
Published: (2022)

Ziprasidone, a second-generation antipsychotic, affects core clock gene mRNA expression in mice
by: Shunpei Moriya, et al.
Published: (2020)

Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
by: Donica Janzen, et al.
Published: (2022)

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
by: Solmi M, et al.
Published: (2017)

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
by: Amy M. VandenBerg, PharmD, BCPP
Published: (2022)

Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics
by: Nicole Moschny, et al.
Published: (2021)

Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics
by: Kirk E Evoy, et al.
Published: (2019)

The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications
by: Hui Chen, et al.
Published: (2023)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
by: Izabela Fulone, et al.
Published: (2021)

Comment on "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: Still Daniel PharmD, BCPP, et al.
Published: (2023)

DILI (drug induced liver injury) in a 9-month-old infant: a rare case of phenobarbital-induced hepatotoxicity
by: Anna Paola Pinna, et al.
Published: (2013)

Atypical pleomorphic adenoma with chronic sialoadenitis of the submandibular gland: a case report in a child
by: Andrea Satta, et al.
Published: (2017)

Editorial: Antipsychotics of New Generation: Where Are We now?
by: Tatiana V. Lipina, et al.
Published: (2021)

Response to comment on the recently published article "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: VandenBerg Amy M. PharmD, BCPP
Published: (2023)

A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
by: Caccia S, et al.
Published: (2013)

The Second Generation
by: Phillips, David Graham, 1867-1911

Neuropsychiatry: psychoses that should not always be treated with antipsychotics
by: Yury P. Sivolap, et al.
Published: (2024)

DIABETES MELLITUS FROM THE POINT OF VIEW OF ADOLESCENTS
by: Larissa Evangelista Ferreira, et al.
Published: (2013)

Antipsychotics and neutropoenia: An update
by: Luis Menéndez Rodríguez, et al.
Published: (2021)

Antidepressant and antipsychotic use in an Italian pediatric population
by: Lombardo Giuseppe, et al.
Published: (2011)

Second and Third Generational Advances in Therapies of the Immune-Mediated Kidney Diseases in Children and Adolescents
by: Ryszard Grenda, et al.
Published: (2022)

Second Generation Patents in Pharmaceutical Innovation
by: Ahn, Hyewon
Published: (2014)

Sleep quality in adolescents with diabetes mellitus
by: Özge Baştopcu, et al.
Published: (2020)

Psoas abscess in an adolescent with diabetes mellitus
by: Maher Al-Hajjaj, et al.
Published: (2021)

Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain
by: Sánchez-Cenizo L, et al.
Published: (2019)

Cariprazine: An Antipsychotic Medication with High Therapeutic Potential
by: Wiktoria, et al.
Published: (2024)

The European Second Generation Compared Does the Integration Context Matter?
Published: (2012)

The European Second Generation Compared Does the Integration Context Matter?
Published: (2012)

Identification of Antipsychotic Side Effects with Glassgow Antipsychotic Side-Effect Scale (GASS)
by: Dita Hasni, et al.
Published: (2020)

SOCIOCULTURAL CHARACTERISTICS OF ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
by: Amanda Newle Sousa Silva, et al.
Published: (2016)

A randomized controlled study to evaluate the effects of lifestyle intervention program for patients with severe mental illness taking Second Generation Antipsychotics (SGAs) in body weight management and monitoring their Body Mass Index (BMI)
by: Daniel Yung-fai Cho, et al.
Published: (2022)

A randomized controlled study to evaluate the effects of lifestyle intervention program for patients with severe mental illness taking Second Generation Antipsychotics (SGAs) in body weight management and monitoring their Body Mass Index (BMI)
by: Daniel Yung-fai Cho, et al.
Published: (2022)

A randomized controlled study to evaluate the effects of lifestyle intervention program for patients with severe mental illness taking Second Generation Antipsychotics (SGAs) in body weight management and monitoring their Body Mass Index (BMI)
by: Daniel Yung-fai Cho, et al.
Published: (2022)

A randomized controlled study to evaluate the effects of lifestyle intervention program for patients with severe mental illness taking Second Generation Antipsychotics (SGAs) in body weight management and monitoring their Body Mass Index (BMI)
by: Daniel Yung-fai Cho, et al.
Published: (2022)

A randomized controlled study to evaluate the effects of lifestyle intervention program for patients with severe mental illness taking Second Generation Antipsychotics (SGAs) in body weight management and monitoring their Body Mass Index (BMI)
by: Daniel Yung-fai Cho, et al.
Published: (2022)